MELVILLE, NY / ACCESSWIRE / May 15, 2024 / As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to reach a value of $232.49 billion by 2032, growing at a CAGR of 13.34% between 2024 and 2032. Medical aesthetics, a subsection of the global aesthetics market, was estimated to be worth $15.4 billion in 2023 and is expected to reach $25.9 billion by 2028 at a CAGR of 11%.

纽约州梅尔维尔/ACCESSWIRE/2024年5月15日/随着技术的进步，更容易增强自然美，2023年价值754.6亿美元的全球美学市场预计到2032年将达到2324.9亿美元，2024年至2032年的复合年增长率为13.34%。医学美学是全球美学市场的一个子市场，2023年估计价值154亿美元，预计到2028年将达到259亿美元，复合年增长率为11%。

BioRestorative Therapies Inc.(NASDAQ:BRTX) intends to elaborate on this commercial platform in connection with its Q1 filing, along with a general business update..

BioRestorative Therapeutics Inc.（纳斯达克股票代码：BRTX）打算在第一季度申报时详细介绍这个商业平台，以及一般的业务更新。。

The increased demand and interest in the expansive aesthetics marketplace have led to the integration of innovative technologies like biotechnology, which could further fuel the growth of the bio-cosmeceuticals market. BioRestorative Therapies is a clinical-stage biotech company leveraging its intellectual property portfolio, core competencies in stem cell biology and current Good Manufacturing Practice (cGMP) to expand into the bio-cosmeceutical space..

对广阔的美学市场日益增长的需求和兴趣导致了生物技术等创新技术的整合，这可能进一步推动生物药妆品市场的增长。生物修复疗法是一家临床阶段的生物技术公司，利用其知识产权组合，干细胞生物学的核心竞争力和当前的良好生产规范（cGMP）扩展到生物药妆领域。。

BioRestorative recently announced signing a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, a leading aesthetics company based in North America. Cartessa is known for its commitment to providing top-notch technologies and unmatched support to professionals in the industry.

BioRestorative最近宣布与北美领先的美学公司Cartessa美学有限责任公司签署了一项为期五年的独家供应协议。Cartessa以致力于为业界专业人士提供一流技术和无与伦比的支持而闻名。

'Cartessa is known for bringing differentiated, non-invasive technologies to the world's best aesthetic providers. To that end, we are thrilled to partner with BioRestorative to introduce a novel and proprietary cell-based innovation within this high-demand market category,' shared Gabe Lubin, founder and CEO of Cartessa.

Cartessa以将差异化的非侵入性技术带给世界上最好的美学供应商而闻名。Cartessa创始人兼首席执行官加布·卢宾（GabeLubin）表示，为此，我们很高兴与BioRestorative合作，在这个高需求市场类别中引入一种新颖且专有的基于细胞的创新。

'Upon mutual consent, the companies will also pursue opportunities to bring additional cell-based biologic products to existing and new aesthetics markets, both at home and abroad. We look forward to keeping our customers and the aesthetics industry at large updated as we progress toward making state-of-the art bio cosmeceuticals more widely available.'.

“经双方同意，两家公司还将寻求机会，为国内外现有和新的美学市场带来更多基于细胞的生物产品。随着我们朝着更广泛地提供最先进的生物药妆品的方向前进，我们期待着不断更新我们的客户和整个美学行业。”。

This agreement aims to leverage BioRestorative's extensive expertise in cell-based biologics, formulation and clinical manufacturing, along with Cartessa's strong presence and capabilities in the professional aesthetics market, including marketing and distribution. BioRestorative also plans to explore the potential of expanding this collaborative relationship to include a wider range of commercialized bio-cosmeceuticals and therapeutics through Investigational New Drug (IND)--enabling studies.

该协议旨在利用BioRestorative在基于细胞的生物制剂，配方和临床制造方面的广泛专业知识，以及Cartessa在专业美学市场（包括营销和分销）中的强大存在和能力。BioRestorative还计划通过研究性新药（IND）-使能研究，探索扩大这种合作关系的潜力，以包括更广泛的商业化生物药妆品和治疗剂。

The ultimate goal is to obtain approvals from the U.S. Food and Drug Administration (FDA) in the emerging bio-cosmeceuticals field..

最终目标是在新兴的生物药妆品领域获得美国食品和药物管理局（FDA）的批准。。

Under the terms of this exclusive five-year agreement, BioRestorative has committed to supplying Cartessa with a predetermined minimum quantity of finished vials of its inaugural cell-based biologic commercial product annually. These vials will be sold under Cartessa's Chronos ExoCR brand as private-label products.

根据这项为期五年的独家协议的条款，BioRestorative承诺每年向Cartessa提供其首个基于细胞的生物商业产品的预定最低成品量。这些小瓶将以Cartessa的Chronos ExoCR品牌作为自有品牌产品销售。

Produced in BioRestorative's ISO-7-certified clean room using a proprietary manufacturing process, this exclusive product consists of a cell-based secretome that contains exosomes, proteins and growth factors. This biologic serum has been specifically designed to reduce the appearance of fine lines and wrinkles and enhance various cosmetic aspects..

该独家产品由含有外泌体，蛋白质和生长因子的基于细胞的分泌组组成，该分泌组在BioRestorative的ISO-7认证的洁净室中使用专有制造工艺生产。这种生物精华液专门用于减少细纹和皱纹的出现，并增强各种美容效果。。

'We believe this strategic agreement with an established aesthetics market leader like Cartessa validates our cell-based biologics platform and represents a transformative step toward our building a strong commercial engine capable of supporting profitable growth while also helping fund the continued advancement of our clinical, BRTX-100, and preclinical, ThermoStem®, pipeline,' said Lance Alstodt, BioRestorative's CEO..

BioRestorative首席执行官兰斯·阿尔斯托德（LanceAlstodt）说：“我们相信，与Cartessa等成熟美学市场领导者达成的这项战略协议，验证了我们基于细胞的生物制剂平台，标志着我们朝着建立一个强大的商业引擎迈出了变革性的一步，该引擎能够支持盈利增长，同时也有助于为我们的临床BRTX-100和临床前ThermoStem®管道的持续发展提供资金。”。。

BioRestorative is not the only pharmaceutical company interested in the medical aesthetics market; companies like AbbVie, Cynosure and Sisram Medical are also investing in the industry.

BioRestorative并不是唯一对医学美学市场感兴趣的制药公司；AbbVie、Cynosure和Sisram Medical等公司也在投资该行业。

Lance Alstodt is hoping to position BioRestorative as a leader, sharing, 'We ended 2023 with approximately $11.1 million in cash, cash equivalents and investments in marketable securities, which did not include net proceeds of $7.6 million from the warrant exchange private placement completed in February.

兰斯·阿尔斯托德（LanceAlstodt）希望将生物修复（BioRestorative）定位为领导者，分享“我们在2023年底拥有约1110万美元的现金、现金等价物和有价证券投资，其中不包括2月份完成的权证交易所私人配售的760万美元净收益。

As a result, we are fortunate to have entered into this transformative agreement with Cartessa while in the enviable position of already having a cash runway well into 2025. This, combined with the meaningful revenues we expect from the commercialization of Chronos ExoCR, should make us significantly less reliant than most of our clinical-stage life sciences company peers on the capital markets going forward.'.

因此，我们很幸运地与Cartessa签订了这项变革性协议，同时在2025年之前已经拥有了一条令人羡慕的资金跑道。再加上我们预计Chronos ExoCR商业化带来的有意义的收入，我们对未来资本市场的依赖程度将大大低于大多数临床阶段生命科学公司同行。”。